LONDON – Convergence Pharmaceuticals Ltd. is to be acquired by Biogen Idec Inc. for up $675 million, just over four years after spinning out of Glaxosmithkline plc (GSK) with a portfolio of ion channel pain drugs that had been parked by the London-based pharma.